Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.

Naoko Miyata; Mitsuhiro Isaka; Hideaki Kojima; Tomohiro Maniwa; Shoji Takahashi; Osamu Takamiya; Yasuhisa Ohde

首页> 外文期刊>General thoracic and cardiovascular surgery >Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.

【24h】

Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.

机译：连续输注重组活化的VII因子以控制患有遗传性VII因子缺乏症的患者在肺叶切除术后的出血。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Inherited factor VII (FVII) deficiency is a rare recessive inherited coagulation disorder with limited available information, especially in patients undergoing major thoracic surgery. In addition, an optimal management strategy for the disease has not been defined. We herein report a case involving a 61-year-old man with asymptomatic FVII deficiency who underwent a right middle and lower lobectomy to treat lung cancer. To the best of our knowledge, the present report is the first to describe the use of recombinant activated FVII continuous infusion for bleeding control after a major thoracic surgery in a patient with inherited FVII deficiency.

机译：遗传因子VII（FVII）缺乏症是一种罕见的隐性遗传性凝血障碍，其可用信息有限，尤其是在进行大胸部手术的患者中。另外，尚未确定该疾病的最佳治疗策略。我们在此报告了一个病例，其中涉及一名无症状FVII缺乏症的61岁男性，该男性患者接受了右中下叶切除术以治疗肺癌。据我们所知，本报告是第一个描述在患有遗传性FVII缺乏症的患者进行大胸部手术后使用重组活化FVII连续输注控制出血的方法。

著录项

来源
《General thoracic and cardiovascular surgery》 |2016年第3期|共4页
作者
Naoko Miyata; Mitsuhiro Isaka; Hideaki Kojima; Tomohiro Maniwa; Shoji Takahashi; Osamu Takamiya; Yasuhisa Ohde;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏血管和淋巴系外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency. [J] . Naoko Miyata, Mitsuhiro Isaka, Hideaki Kojima, General thoracic and cardiovascular surgery . 2016,第3期

机译：连续输注重组活化的VII因子以控制患有遗传性VII因子缺乏症的患者在肺叶切除术后的出血。
2. Critique of ‘Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial' ☆Critique of: Richard P. Dutton, Michael Parr, Bartholomew J. Tortella et al. Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial, The Journal of TRAUMA Injury, Infection, and Critical Care. Volume 71, Number 1, July 2011 [J] . Husham Abdul Rahman, Mazin A. Tuma, Rifat Latifi, Journal of Emergency Medicine, Trauma and Acute Care . 2012,第2期

机译：批评“创伤患者中重组活化因子VII的安全性：来自对照试验的结果”☆批评：Richard P. Dutton，Michael Parr，Bartholomew J. Tortella等。创伤患者中重组活化的因子的安全性：对照试验，《创伤，损伤和重症护理杂志》的结果。 2011年7月第71卷第1期
3. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). [J] . Johannessen M, Nielsen G, Nordfang O Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis . 2000,第Suppla1期

机译：因子VII：C凝块分析和改良的活化因子VII分析在监测重组活化因子VII（NovoSeven）治疗的患者中监测因子VII活性的比较。
4. Human Cell Line Shows Better Expression Level for Recombinant Factor VII Production [C] . Marcela C.C, Freitas, Aline S. Bomfim, Protein Engineering Summit. . 2018

机译：人细胞系显示重组因子VII生产的更好的表达水平
5. Thermodynamic and hydrodynamic behavior of the tissue factor:factor VII(a) complex [D] . Waxman, Evan. 1993

机译：组织因子VII（a）复合物的热力学和流体力学行为
6. Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency [O] . Madhvi Rajpurkar, David L Cooper 2018

机译：连续输注重组活化因子VII：先天性血友病抑制剂和先天性凝血因子VII缺乏症的资料回顾
7. Critique of ‘Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial’ ☆☆Critique of: Richard P. Dutton, Michael Parr, Bartholomew J. Tortella et al. Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial, The Journal of TRAUMA Injury, Infection, and Critical Care. Volume 71, Number 1, July 2011 [O] . Yassir S. Abdulrahman, Mazin A. Tuma, Husham Abdul Rahman, 2012

机译：“创伤患者中重组活化因子VII安全性的评价：对照试验的结果”☆☆批判：Richard p. Dutton，michael parr，Bartholomew J. Tortella等。创伤患者的重组活化因子VII安全性：对照试验，TRaUma损伤，感染和重症监护杂志的结果。第71卷，第1期，2011年7月
8. Prolonged Prothrombin Time After Recombinant Activated Factor VII Therapy in Critically Bleeding Trauma Patients Is Associated With Adverse Outcomes. [R] . McMullin, N. R., Wade, C. E., Holcomb, J. B., 2010

机译：重组活化因子VII治疗后严重出血创伤患者的凝血酶原时间延长与不良后果相关。

Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.

摘要

著录项

相似文献

相关主题

期刊订阅